TW200637863A - Organic compounds - Google Patents

Organic compounds

Info

Publication number: TW200637863A
Authority: TW; Taiwan
Prior art keywords: compounds; organic compounds; adenosine; meanings; receptor
Prior art date: 2005-01-14

Application number

TW095101304A

Other languages

English (en)

Inventor

Robin Alec Fairhurst

Roger John Taylor

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-01-14

Filing date

2006-01-13

Publication date

2006-11-01

2006-01-13 Application filed by Novartis Ag filed Critical Novartis Ag

2006-11-01 Publication of TW200637863A publication Critical patent/TW200637863A/zh

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Diabetes (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Ophthalmology & Optometry (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Neurosurgery (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

TW095101304A 2005-01-14 2006-01-13 Organic compounds TW200637863A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0500785.1A GB0500785D0 (en)	2005-01-14	2005-01-14	Organic compounds

Publications (1)

Publication Number	Publication Date
TW200637863A true TW200637863A (en)	2006-11-01

Family

ID=34224620

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW095101304A TW200637863A (en)	2005-01-14	2006-01-13	Organic compounds

Country Status (31)

Country	Link
US (1)	US8114877B2 (zh)
EP (1)	EP1841768B1 (zh)
JP (1)	JP2008526911A (zh)
KR (1)	KR20070093424A (zh)
CN (1)	CN101107249B (zh)
AR (1)	AR052659A1 (zh)
AT (1)	ATE414085T1 (zh)
AU (1)	AU2006205878B2 (zh)
BR (1)	BRPI0606324A2 (zh)
CA (1)	CA2593398A1 (zh)
CY (1)	CY1108752T1 (zh)
DE (1)	DE602006003628D1 (zh)
DK (1)	DK1841768T3 (zh)
ES (1)	ES2317483T3 (zh)
GB (1)	GB0500785D0 (zh)
GT (1)	GT200600013A (zh)
HR (1)	HRP20090061T3 (zh)
IL (1)	IL184149A0 (zh)
MA (1)	MA29170B1 (zh)
MX (1)	MX2007008557A (zh)
MY (1)	MY141727A (zh)
NO (1)	NO20074050L (zh)
PE (1)	PE20060833A1 (zh)
PL (1)	PL1841768T3 (zh)
PT (1)	PT1841768E (zh)
RU (1)	RU2400483C2 (zh)
SI (1)	SI1841768T1 (zh)
TN (1)	TNSN07268A1 (zh)
TW (1)	TW200637863A (zh)
WO (1)	WO2006074925A1 (zh)
ZA (1)	ZA200704743B (zh)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GT200500281A (es) *	2004-10-22	2006-04-24	Novartis Ag	Compuestos organicos.
GB0500785D0 (en)	2005-01-14	2005-02-23	Novartis Ag	Organic compounds
GB0505219D0 (en) *	2005-03-14	2005-04-20	Novartis Ag	Organic compounds
GB0607945D0 (en) *	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
GB0607944D0 (en) *	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
GB0607951D0 (en) *	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
GB0607948D0 (en) *	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
RU2457209C2 (ru) *	2006-04-21	2012-07-27	Новартис Аг	Производные пурина, предназначенные для применения в качестве агонистов аденозинового рецептора а2а
GB0607950D0 (en) *	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
GB0607954D0 (en) *	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
GB0607953D0 (en) *	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
EP1889846A1 (en) *	2006-07-13	2008-02-20	Novartis AG	Purine derivatives as A2a agonists
EP1903044A1 (en) *	2006-09-14	2008-03-26	Novartis AG	Adenosine Derivatives as A2A Receptor Agonists
RU2009121819A (ru) *	2006-11-10	2010-12-20	Новартис АГ (CH)	Производные моноацетата циклопентендиола
US20100152210A1 (en) *	2007-03-28	2010-06-17	Neuro Search A/S/	Purinyl derivatives and their use as potassium channel modulators
US9296776B2 (en)	2007-07-09	2016-03-29	Eastern Virginia Medical School	Substituted nucleoside derivatives with antiviral and antimicrobial properties
KR20100068286A (ko) *	2007-10-17	2010-06-22	노파르티스 아게	아데노신 ａ1 수용체 리간드로서의 퓨린 유도체
WO2010106145A1 (en) *	2009-03-20	2010-09-23	Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.	Oxidated derivatives of triazolypurines useful as ligands of the adenosine a2a receptor and their use as medicaments
JP2012532140A (ja)	2009-06-30	2012-12-13	フォレスト・ラボラトリーズ・ホールディングス・リミテッド	Ａ２ａｒ作動薬としてのアルコキシ−カルボニル−アミノ−アルキニル−アデノシン化合物及びその誘導体
WO2013144191A1 (de)	2012-03-29	2013-10-03	Bayer Intellectual Property Gmbh	Substituierte 2 -amino - 3 - cyanopyridine als inhibitoren des natrium calcium austausches und ihre verwendung bei kardiovaskulären erkrankungen
AU2013283488A1 (en)	2012-06-26	2015-01-15	Saniona Aps	A phenyl triazole derivative and its use for modulating the GABAA receptor complex
CN109563034A (zh) *	2016-06-08	2019-04-02	葛兰素史密斯克莱知识产权发展有限公司	化学化合物
WO2018160824A1 (en) *	2017-03-01	2018-09-07	Prelude Therapeutics, Incorporated	Selective inhibitors of protein arginine methyltransferase 5 (prmt5)

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1528382A (en)	1974-12-26	1978-10-11	Teijin Ltd	Cyclopentene diols and acyl esters thereof and processes for their preparation
US4738954A (en)	1985-11-06	1988-04-19	Warner-Lambert Company	Novel N6 -substituted-5'-oxidized adenosine analogs
US4873360A (en)	1986-07-10	1989-10-10	Board Of Governors Of Wayne State University	Process for the preparation of cyclopentanoids and novel intermediates produced thereby
IL84414A0 (en) *	1986-11-14	1988-04-29	Ciba Geigy Ag	N9-cyclopentyl-substituted adenine derivatives
US4954504A (en)	1986-11-14	1990-09-04	Ciba-Geigy Corporation	N9 -cyclopentyl-substituted adenine derivatives having adenosine-2 receptor stimulating activity
JP2586897B2 (ja)	1987-03-09	1997-03-05	富士薬品工業株式会社	光学活性なシス−シクロペンテン−３，５−ジオ−ルモノエステルの製造法
EP0550631B1 (en)	1990-09-25	1997-01-02	Rhone-Poulenc Rorer International (Holdings) Inc.	Compounds having antihypertensive and anti-ischemic properties
IT1254915B (it)	1992-04-24	1995-10-11	Gloria Cristalli	Derivati di adenosina ad attivita' a2 agonista
GB9301000D0 (en) *	1993-01-20	1993-03-10	Glaxo Group Ltd	Chemical compounds
US5688774A (en)	1993-07-13	1997-11-18	The United States Of America As Represented By The Department Of Health And Human Services	A3 adenosine receptor agonists
US5691188A (en)	1994-02-14	1997-11-25	American Cyanamid Company	Transformed yeast cells expressing heterologous G-protein coupled receptor
US5688744A (en) *	1995-11-03	1997-11-18	Rohm And Haas Company	Antimicrobial compounds with quick speed of kill
ES2178725T3 (es)	1996-01-02	2003-01-01	Aventis Pharma Inc	Procedimiento para preparar 2,4-dihidroxipiridina y 2,4-dihidroxi-3-nitropiridina.
US6376472B1 (en)	1996-07-08	2002-04-23	Aventis Pharmaceuticals, Inc.	Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
TW528755B (en) *	1996-12-24	2003-04-21	Glaxo Group Ltd	2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
AU750322B2 (en)	1997-05-09	2002-07-18	Trustees Of The University Of Pennsylvania, The	Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
GB9813535D0 (en) *	1998-06-23	1998-08-19	Glaxo Group Ltd	Chemical compounds
GB9813565D0 (en) *	1998-06-23	1998-08-19	Glaxo Group Ltd	Chemical compounds
GB9813554D0 (en) *	1998-06-23	1998-08-19	Glaxo Group Ltd	Chemical compounds
CN1313861A (zh) *	1998-06-23	2001-09-19	葛兰素集团有限公司	2－(嘌呤－9－基)－四氢呋喃－3,4－二醇衍生物
GB9813540D0 (en)	1998-06-23	1998-08-19	Glaxo Group Ltd	Chemical compounds
AU5879299A (en)	1998-10-16	2000-05-08	Monaghan, Sandra Marina	Adenine derivatives
PT1140933E (pt)	1998-12-31	2004-12-31	Aventis Pharma Inc	Processo para preparar derivados n6-substituidos de desaza-adenosina
US7427606B2 (en)	1999-02-01	2008-09-23	University Of Virginia Patent Foundation	Method to reduce inflammatory response in transplanted tissue
GB9913932D0 (en) *	1999-06-15	1999-08-18	Pfizer Ltd	Purine derivatives
US6322771B1 (en)	1999-06-18	2001-11-27	University Of Virginia Patent Foundation	Induction of pharmacological stress with adenosine receptor agonists
US6403567B1 (en)	1999-06-22	2002-06-11	Cv Therapeutics, Inc.	N-pyrazole A2A adenosine receptor agonists
US6214807B1 (en)	1999-06-22	2001-04-10	Cv Therapeutics, Inc.	C-pyrazole 2A A receptor agonists
US6586413B2 (en)	1999-11-05	2003-07-01	The United States Of America As Represented By The Department Of Health And Human Services	Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
GB0003960D0 (en)	2000-02-18	2000-04-12	Pfizer Ltd	Purine derivatives
GB0022695D0 (en) *	2000-09-15	2000-11-01	Pfizer Ltd	Purine Derivatives
CA2434906C (en)	2001-01-16	2008-08-19	Can-Fite Biopharma Ltd.	Use of an adenosine a3 receptor agonist for inhibition of viral replication
GB2372741A (en)	2001-03-03	2002-09-04	Univ Leiden	C2,8-Disubstituted adenosine derivatives and their different uses
US20040162422A1 (en)	2001-03-20	2004-08-19	Adrian Hall	Chemical compounds
EP1258247A1 (en)	2001-05-14	2002-11-20	Aventis Pharma Deutschland GmbH	Adenosine analogues for the treatment of insulin resistance syndrome and diabetes
NZ532062A (en)	2001-10-01	2006-09-29	Univ Virginia	2-propynyl adenosine analogues having A2 adenosine recepter agonist activity and compositions thereof to treat inflammatory responses
US7414036B2 (en)	2002-01-25	2008-08-19	Muscagen Limited	Compounds useful as A3 adenosine receptor agonists
DE60318192T2 (de)	2002-04-10	2008-04-30	The University Of Virginia Patent Foundation	Verwendung von a2a adenosin rezeptor agonisten und anti-pathogene mittel enthaltenden kombinationen zur behandlung von entzündungskrankheiten
WO2005063246A1 (en)	2003-12-29	2005-07-14	Can-Fite Biopharma Ltd.	Method for treatment of multiple sclerosis
MXPA06010075A (es)	2004-03-05	2007-04-10	Cambridge Biotechnology Ltd	Compuestos terapeuticos.
EP1746885A4 (en)	2004-05-03	2010-09-08	Univ Virginia	AGONISTS OF A2A ADENOSINE RECEPTORS FOR THE TREATMENT OF NEEDLE INJURY IN DIABETES
PE20060272A1 (es)	2004-05-24	2006-05-22	Glaxo Group Ltd	(2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
US7825102B2 (en)	2004-07-28	2010-11-02	Can-Fite Biopharma Ltd.	Treatment of dry eye conditions
JP4642847B2 (ja)	2004-07-28	2011-03-02	キャン−ファイト・バイオファーマ・リミテッド	シェーグレン症候群を含むドライアイ疾患治療用アデノシンａ３レセプターアゴニスト
CA2601996A1 (en)	2004-09-09	2006-03-23	Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services	Purine derivatives as a3 and a1 adenosine receptor agonists
GT200500281A (es)	2004-10-22	2006-04-24	Novartis Ag	Compuestos organicos.
US20080051364A1 (en)	2004-11-08	2008-02-28	Pninna Fishman	Therapeutic Treatment of Accelerated Bone Resorption
GB0500785D0 (en)	2005-01-14	2005-02-23	Novartis Ag	Organic compounds
CA2596424C (en)	2005-02-04	2016-03-29	Millennium Pharmaceuticals, Inc.	Inhibitors of e1 activating enzymes
GB0505219D0 (en)	2005-03-14	2005-04-20	Novartis Ag	Organic compounds
GB0514809D0 (en)	2005-07-19	2005-08-24	Glaxo Group Ltd	Compounds
KR101101252B1 (ko)	2005-11-30	2012-01-04	캔-파이트 바이오파마 리미티드	골관절염 치료를 위한 ａ3 아데노신 수용체 아고니스트의용도
WO2007089507A1 (en)	2006-01-26	2007-08-09	The Government Of The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services	A3 adenosine receptor allosteric modulators
ES2593433T3 (es)	2006-02-02	2016-12-09	Millennium Pharmaceuticals, Inc.	Inhibidores de las enzimas activadoras E1
WO2007092936A2 (en)	2006-02-08	2007-08-16	University Of Virginia Patent Foundation	Method to treat gastric lesions
GB0607945D0 (en)	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
RU2457209C2 (ru)	2006-04-21	2012-07-27	Новартис Аг	Производные пурина, предназначенные для применения в качестве агонистов аденозинового рецептора а2а
GB0607954D0 (en) *	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
GB0607944D0 (en) *	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
GB0607953D0 (en)	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
GB0607950D0 (en)	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
GB0607951D0 (en)	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
GB0607948D0 (en)	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
EP1889846A1 (en) *	2006-07-13	2008-02-20	Novartis AG	Purine derivatives as A2a agonists
US8008307B2 (en)	2006-08-08	2011-08-30	Millennium Pharmaceuticals, Inc.	Heteroaryl compounds useful as inhibitors of E1 activating enzymes
EP1903044A1 (en)	2006-09-14	2008-03-26	Novartis AG	Adenosine Derivatives as A2A Receptor Agonists
RU2009121819A (ru)	2006-11-10	2010-12-20	Новартис АГ (CH)	Производные моноацетата циклопентендиола
WO2008124150A1 (en)	2007-04-09	2008-10-16	University Of Virginia Patent Foundation	Method of treating enteritis, intestinal damage, and diarrhea from c. difficile with an a2a adenosine receptor agonist
US20080262001A1 (en)	2007-04-23	2008-10-23	Adenosine Therapeutics, Llc	Agonists of a2a adenosine receptors for treating recurrent tumor growth in the liver following resection
US8153781B2 (en)	2007-06-29	2012-04-10	The United States Of America As Represented By The Secretary, Department Of Health And Human Services	Dendrimer conjugates of agonists and antagonists of the GPCR superfamily
KR20100068286A (ko) *	2007-10-17	2010-06-22	노파르티스 아게	아데노신 ａ1 수용체 리간드로서의 퓨린 유도체
US20090181934A1 (en)	2007-10-17	2009-07-16	Novartis Ag	Organic Compounds
WO2009061516A1 (en)	2007-11-08	2009-05-14	New York University School Of Medicine	Medical implants containing adenosine receptor agonists and methods for inhibiting medical implant loosening
EA201001135A1 (ru)	2008-01-09	2011-02-28	ПиДжиИксХЭЛС ЭлЭлСи	Интратекальное лечение невропатической боли агонистами ar

2005
- 2005-01-14 GB GBGB0500785.1A patent/GB0500785D0/en not_active Ceased
2006
- 2006-01-06 MY MYPI20060048A patent/MY141727A/en unknown
- 2006-01-11 GT GT200600013A patent/GT200600013A/es unknown
- 2006-01-12 KR KR1020077016098A patent/KR20070093424A/ko not_active Ceased
- 2006-01-12 AT AT06700452T patent/ATE414085T1/de active
- 2006-01-12 ES ES06700452T patent/ES2317483T3/es not_active Expired - Lifetime
- 2006-01-12 CA CA002593398A patent/CA2593398A1/en not_active Abandoned
- 2006-01-12 SI SI200630194T patent/SI1841768T1/sl unknown
- 2006-01-12 HR HR20090061T patent/HRP20090061T3/xx unknown
- 2006-01-12 AR ARP060100129A patent/AR052659A1/es not_active Application Discontinuation
- 2006-01-12 DE DE602006003628T patent/DE602006003628D1/de not_active Expired - Lifetime
- 2006-01-12 US US11/722,835 patent/US8114877B2/en not_active Expired - Fee Related
- 2006-01-12 RU RU2007130802/04A patent/RU2400483C2/ru not_active IP Right Cessation
- 2006-01-12 PT PT06700452T patent/PT1841768E/pt unknown
- 2006-01-12 AU AU2006205878A patent/AU2006205878B2/en not_active Ceased
- 2006-01-12 WO PCT/EP2006/000217 patent/WO2006074925A1/en not_active Ceased
- 2006-01-12 EP EP06700452A patent/EP1841768B1/en not_active Expired - Lifetime
- 2006-01-12 JP JP2007550752A patent/JP2008526911A/ja active Pending
- 2006-01-12 PL PL06700452T patent/PL1841768T3/pl unknown
- 2006-01-12 MX MX2007008557A patent/MX2007008557A/es active IP Right Grant
- 2006-01-12 CN CN2006800024512A patent/CN101107249B/zh not_active Expired - Fee Related
- 2006-01-12 DK DK06700452T patent/DK1841768T3/da active
- 2006-01-12 BR BRPI0606324-1A patent/BRPI0606324A2/pt not_active IP Right Cessation
- 2006-01-13 TW TW095101304A patent/TW200637863A/zh unknown
- 2006-01-13 PE PE2006000062A patent/PE20060833A1/es not_active Application Discontinuation
2007
- 2007-06-20 ZA ZA200704743A patent/ZA200704743B/xx unknown
- 2007-06-21 IL IL184149A patent/IL184149A0/en unknown
- 2007-07-13 TN TNP2007000268A patent/TNSN07268A1/en unknown
- 2007-07-26 MA MA30103A patent/MA29170B1/fr unknown
- 2007-08-06 NO NO20074050A patent/NO20074050L/no not_active Application Discontinuation
2009
- 2009-02-05 CY CY20091100134T patent/CY1108752T1/el unknown

Also Published As

Publication number	Publication date
ATE414085T1 (de)	2008-11-15
IL184149A0 (en)	2007-10-31
MA29170B1 (fr)	2008-01-02
EP1841768B1 (en)	2008-11-12
AU2006205878B2 (en)	2009-10-22
PL1841768T3 (pl)	2009-04-30
HK1112458A1 (zh)	2008-09-05
EP1841768A1 (en)	2007-10-10
BRPI0606324A2 (pt)	2009-06-16
GB0500785D0 (en)	2005-02-23
PT1841768E (pt)	2009-02-05
HRP20090061T3 (en)	2009-03-31
WO2006074925A1 (en)	2006-07-20
CN101107249A (zh)	2008-01-16
AR052659A1 (es)	2007-03-28
AU2006205878A1 (en)	2006-07-20
RU2400483C2 (ru)	2010-09-27
ZA200704743B (en)	2008-08-27
KR20070093424A (ko)	2007-09-18
PE20060833A1 (es)	2006-10-13
SI1841768T1 (sl)	2009-04-30
CN101107249B (zh)	2010-10-13
RU2007130802A (ru)	2009-02-20
CA2593398A1 (en)	2006-07-20
DE602006003628D1 (de)	2008-12-24
TNSN07268A1 (en)	2008-12-31
MY141727A (en)	2010-06-15
NO20074050L (no)	2007-09-17
DK1841768T3 (da)	2009-03-02
US8114877B2 (en)	2012-02-14
MX2007008557A (es)	2007-08-14
CY1108752T1 (el)	2014-04-09
ES2317483T3 (es)	2009-04-16
US20080207648A1 (en)	2008-08-28
JP2008526911A (ja)	2008-07-24
GT200600013A (es)	2006-08-02

Publication	Publication Date	Title
TW200637863A (en)	2006-11-01	Organic compounds
TN2010000167A1 (en)	2011-11-11	Organic compounds
TN2009000084A1 (en)	2010-08-19	Adenosine derivatives as a2a receptor agonists
TW200628154A (en)	2006-08-16	Organic compounds
ZA201000079B (en)	2010-09-29	Organic compounds
TNSN07154A1 (en)	2008-11-21	Purine derivatives for use as adenosin a-2a receptor agonists
MX2009004715A (es)	2009-05-20	Compuestos heterociclicos como agentes antiinflamatorios.
GB0417910D0 (en)	2004-09-15	Organic compounds
GB0510584D0 (en)	2005-06-29	Organic compounds
TN2010000305A1 (en)	2011-11-11	Pyrrolopyrimidines and pyrrolopyridines
TW200722079A (en)	2007-06-16	Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
TNSN08544A1 (en)	2010-04-14	Purine derivatives as a2a agonists
MX2009007713A (es)	2009-07-29	Derivados de piridazina, procedimientos para su preparacion y su uso como fungicidas.
TW200630374A (en)	2006-09-01	Thiazolyldihydroindazoles
GB0428416D0 (en)	2005-02-02	Organic compounds
WO2007068473A3 (en)	2007-08-23	Organic compounds
TW200738611A (en)	2007-10-16	9-Chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments
GB0417801D0 (en)	2004-09-15	Organic compounds
GB0417804D0 (en)	2004-09-15	Organic compounds
GB0402101D0 (en)	2004-03-03	Organic compounds
TNSN08536A1 (en)	2010-04-14	Quinolinone derivatives and their pharmaceutical compositions
UA93197C2 (ru)	2011-01-25	Производные пиразолиламинопиридина, способ их получения, их применения и фармацевтическая композиция (варианты)